Entrada Therapeutics (TRDA) Net Cash Flow (2020 - 2026)

Entrada Therapeutics' Net Cash Flow history runs 7 years deep, the most recent figure standing at -$14.6 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 56.23% year-over-year to -$14.6 million; the TTM figure through Mar 2026 stood at $7.9 million (up 1427.05% YoY), while the FY2025 annual figure was -$10.8 million, down 132.18% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$14.6 million, down from -$2.9 million in the prior quarter.
• The five-year high for Net Cash Flow was $182.5 million in Q1 2023, with the low at -$202.5 million in Q1 2022.
• The 5-year median for Net Cash Flow is -$2.9 million (2025), against an average of -$12.4 million.
• The sharpest annual moves came in 2023 and 2025: Net Cash Flow surged 292.79% in 2023, then sank 4101.68% in 2025.
• Entrada Therapeutics' Net Cash Flow stood at -$8.2 million in 2022, then soared by 292.79% to $15.7 million in 2023, then surged by 47.34% to $23.2 million in 2024, then slumped by 112.49% to -$2.9 million in 2025, then slumped by 405.12% to -$14.6 million in 2026.
• Business Quant data shows TRDA's Net Cash Flow at -$14.6 million in Q1 2026, -$2.9 million in Q4 2025, and $20.8 million in Q3 2025.